Grants per year
- 1 - 25 out of 66 results
Search results
-
Active
-
Molecular mechanism underlying clonal expansion of hematopoietic stem cells
Liu, Y. (PD/PI), Abaza, Y. (Co-Investigator), Altman, J. K. (Co-Investigator) & Bartom, E. T. (Co-Investigator)
National Heart, Lung, and Blood Institute
4/1/24 → 3/31/28
Project: Research project
-
Prot #KO-MEN-007: Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination with Ziftomenib (KO-539) or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination with Ziftomenib for the Treatment of Patients with Acute Myeloi
Altman, J. K. (PD/PI)
Quintiles, Inc., Kura Oncology, Inc.
3/12/24 → 3/12/27
Project: Research project
-
Prot #TAK-012-1501: A Phase 1/2a, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety and Efficacy of GDX012 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Altman, J. K. (PD/PI)
PPD Investigator Services, LLC, Takeda Development Center Americas, Inc.
11/14/23 → 11/14/26
Project: Research project
-
Prot #2215-CL-0203: A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible fo
Altman, J. K. (PD/PI)
Parexel, Astellas Pharma Global Development, Inc.
3/13/23 → 3/13/26
Project: Research project
-
Liquid Biopsy to Measure Novel Biomarkers of ImmunoMetabolic Cancer Risk (IMCR)
Thaxton, C. S. (PD/PI), Thaxton, C. S. (PD/PI), Abaza, Y. (Co-Investigator), Abaza, Y. (Co-Investigator), Altman, J. K. (Co-Investigator), Altman, J. K. (Co-Investigator), Behdad, A. (Co-Investigator), Behdad, A. (Co-Investigator), Griffith, J. W. (Other) & Griffith, J. W. (Other)
V Foundation for Cancer Research
8/1/22 → 8/1/25
Project: Research project
-
Prot #APTO-CG-806-03: A Phase 1a/b Trial of CG-806 in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Altman, J. K. (PD/PI)
1/27/21 → 1/27/27
Project: Research project
-
Prot #AT148002: A Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome (MDS)
Altman, J. K. (PD/PI)
Novella Clinical, LLC, ALX Oncology, Inc
9/23/20 → 9/23/26
Project: Research project
-
Prot #PrE0905: Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Altman, J. K. (PD/PI)
Alpha Oncology, Inc., PrECOG, LLC
1/30/20 → 1/30/26
Project: Research project
-
Targeting Novel Protein Complexes for the Treatment of Acute Myeloid Leukemia
Platanias, L. C. (PD/PI), Platanias, L. C. (PD/PI), Platanias, L. C. (PD/PI), Beauchamp, E. M. (Co-Investigator), Beauchamp, E. M. (Co-Investigator), Beauchamp, E. M. (Co-Investigator), Eklund, E. A. (Co-Investigator), Eklund, E. A. (Co-Investigator), Eklund, E. A. (Co-Investigator), Altman, J. K. (Other), Altman, J. K. (Other) & Altman, J. K. (Other)
6/1/19 → 5/31/25
Project: Research project
-
Prot #CSTI571A2406: An open label, multi-center imatinib roll-over protocol for patients who have completed a previous Novartis-sponsored imatinib study and are judged by the investigator to benefit from continued imatinib treatment
Altman, J. K. (PD/PI)
Novartis Pharmaceuticals Corporation
12/1/12 → 4/30/34
Project: Research project
-
Finished
Prot #TL-895-203: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with KRT-232 in Subjects with Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)
Altman, J. K. (PD/PI)
PSI Pharma Support America Inc., Telios Pharma, Inc.
5/4/21 → 5/4/24
Project: Research project
-
Prot #LOXO-IDH-20001: A Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations
Altman, J. K. (PD/PI)
Medpace Clinical Research LLC, Loxo Oncology, Inc.
3/23/21 → 3/23/24
Project: Research project
-
Prot #KRT-232-104: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML)
Altman, J. K. (PD/PI)
INC Research, LLC, Kartos Therapeutics, Inc.
2/5/20 → 2/5/23
Project: Research project
-
Prot #A19-11184: Phase I Study of APR-246 in Combination with Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
Altman, J. K. (PD/PI)
Theradex, Aprea Therapeutics AB
1/21/20 → 1/21/23
Project: Research project
-
Prot #CP-MGD006-01: A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Ri
Altman, J. K. (PD/PI)
7/5/19 → 7/5/22
Project: Research project
-
Prot #2215-CL-1101: Phase 1/2 Study of ASP2215 (Gilteritinib) Combined with Atezolizumab in Patients with Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)
Altman, J. K. (PD/PI)
Syneos Health, Inc., Astellas Pharma Global Development, Inc.
4/23/19 → 11/15/21
Project: Research project
-
Prot #BAY 1436032/19036: An open-label, non-randomized, multicenter Phase I study to determine the maximum tolerated and/or recommended Phase II dose of oral mutant IDH1 (mIDH1) inhibitor BAY 1436032 and to characterize its safety, tolerability, pharmacok
Altman, J. K. (PD/PI)
Covance Inc., Bayer HealthCare Pharmaceuticals, Inc.
2/22/18 → 6/1/19
Project: Research project